Metastatic breast cancer Press Release
|06/16/2020 - 09:19||
Patricia S. Steeg, PhD, to Receive 2020 AACR-Women in Cancer Research Charlotte Friend Lectureship
PHILADELPHIA — The American Association for Cancer Research (AACR) is honoring Patricia S. Steeg, PhD, with the 2020 AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship.
|05/18/2020 - 02:40||
ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Tokyo, Basking Ridge, NJ and Munich - (May 18, 2020) ? Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca?s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.
|05/12/2020 - 06:32||
Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer, who have previously received two or more anti-HER2 regimens in any setting, including trastuzumab, pertuzumab and trastuzumab-emtansine (T–DM1).
|05/11/2020 - 03:28||
ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
Tokyo, Basking Ridge, NJ and Munich – (May 11, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
|04/20/2020 - 05:50||
Seattle Genetics Announces U.S. FDA Approval of TUKYSA (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable (cannot be surgically removed) or metastatic HER2-positive breast cancer, including patients with brain metastases (disease that has spread to the brain), who have received one or more prior anti-HER2-based regimens in the metastatic setting.
|04/15/2020 - 16:38||
COVID-19 and Cancer: A Conversation with Cancer Control Expert Otis Brawley, MD
NCCS has been collecting questions from patients and survivors on the coronavirus crisis and decided to address these questions through a series of webinars and podcasts. Last week, NCCS hosted a conversation with cancer control expert and epidemiologist Otis Brawley, MD. Watch the full video conversation and read excerpted portions below.
|03/25/2020 - 07:55||
ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
Tokyo, Munich and Basking Ridge, NJ – March 25, 2020 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the approval of ENHERTU® (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), in Japan for the treatment of patients with HER2 positive unresectable or recurrent breast cancer after prior chemotherapy (limit the use to patients who are refractory or intolerant to standard treatments).
|03/19/2020 - 11:17||
A Protein That Helps Trap Bacteria May Contribute to Metastasis in a Mouse Model of Breast Cancer
PHILADELPHIA – The protein peptidyl arginine deiminase 4 (PAD4), which enables some immune cells to trap bacteria, promoted breast cancer metastasis in mice when expressed in cancer cells, according to data published in Molecular Cancer Research, a journal of the American Association for Cancer Research.
|03/16/2020 - 12:54||
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA (trastuzumab-pkrb) for Injection
Adjuvant Breast Cancer HERZUMA is indicated for the adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy.
|03/11/2020 - 07:02||
Researchers identify marker that may predict whether lung cancer likely to spread
Tony Hu is the Weatherhead Presidential Chair in Biotechnology Innovation at Tulane University School of Medicine.
|03/09/2020 - 15:22||
Cancerous tumors, surrounding cells illuminated by new imaging agent
Click to share on Facebook (Opens in new window) Click to share on Twitter (Opens in new window) Click to share on Pinterest (Opens in new window) Click to share on LinkedIn (Opens in new window)
|02/05/2020 - 08:59||
How cancer metabolism could be key for new therapies
Biochemist Michael Lukey joins Cold Spring Harbor Laboratory (CSHL) as the newest addition to its National Cancer Institute-designated Cancer Center. Lukey studies the metabolic reprogramming events that cancer cells undergo to feed tumor growth. He works on identifying vulnerabilities in these metabolic processes that can be targets for cancer therapy, including when breast cancer metastasizes to the brain.
|01/30/2020 - 04:15||
First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
The dose-escalating study will enroll up to 12 individuals with metastatic, hormone receptor positive breast cancer with stable or minimally progressive disease, including bone metastasis. GMI-1359 is a dual inhibitor of both E-selectin and CXCR4. The trial is designed to evaluate safety, pharmacokinetics and pharmacodynamic measures of biologic activity, such as increases in circulating tumor cells and mobilization of CD34+ and immune T-cell subsets.
|01/27/2020 - 10:12||
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
Tokyo, Munich and Basking Ridge, NJ – (January 27, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (ADC), in patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy.
|01/27/2020 - 09:16||
Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer
|01/10/2020 - 01:40||
LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched the in-house developed anticancer agent Halaven® (product name in China: 海乐卫®, generic name: eribulin mesylate) in China.
|01/07/2020 - 05:51||
ENHERTU Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
Tokyo and Basking Ridge, NJ – (January 6, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate, is now available by prescription in the U.S.
|12/30/2019 - 17:45||
LYNPARZA (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
LYNPARZA Reduced the Risk of Disease Progression or Death by 47% Compared to Placebo in Patients Whose Disease Had Not Progressed On at Least 16 Weeks of a First-Line Platinum-Based Chemotherapy Regimen.
|12/22/2019 - 22:39||
ENHERTU Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
Tokyo, Munich and Basking Ridge, NJ – (December 20, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC), for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
|12/20/2019 - 14:01||
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
|12/19/2019 - 04:58||
European Commission approves Roches Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Kadcyla in early breast cancer represents a new option after neoadjuvant treatment for this group of patients who are known to have a worse prognosis Approval based on KATHERINE trial data showing Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting.
|12/18/2019 - 08:05||
Using AI to understand the spread of cancer
Researchers at the Technical University of Munich (TUM), the Helmholtz Zentrum München and the LMU Munich have developed a new algorithm that automatically detects metastases. The new technology uses artificial intelligence (AI) and even finds single disseminated cancer cells in the body of mice. In this way, the spread mechanisms of different types of cancer can be investigated in more detail.
|12/17/2019 - 16:03||
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
ODAC voted that Lynparza demonstrated a clinically meaningful and favourable risk-benefit profile for patients based on Phase III POLO trial results
|12/16/2019 - 01:22||
Nine patients given another chance at life will ride City of Hopes 2020 Rose Parade float
DUARTE, Calif. — Nine patients will ride City of Hope’s eponymous float at the 131st Rose Parade® presented by Honda on New Year’s Day. These survivors demonstrate how “The Power of Hope” and leading-edge treatment at a biomedical research institution gave them the gift of time.
|City of Hope Na...|
|12/14/2019 - 09:35||
News digest NHS drug decisions, leukaemia treatment trials and long term anastrozole benefits
The Institute of Cancer Research has warned that focusing on the cure for cancer as the ‘holy grail’ of cancer research has undermined people’s understanding of how much progress has been made in the field. Researchers conducted a survey which analysed the public and patient opinion of cancer as a long-term, manageable disease. Reported in The Guardian, the results showed that only 28 out of 100 of people believe cancers can be controlled long-term despite the fact that, on average, people are living for more than 10 years after a cancer diagnosis.
|Cancer Research UK|